Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials

Tao Fu, Zhao-De Bu, Zi-Yu Li, Lian-Hai Zhang, Xiao-Jiang Wu, Ai-Wen Wu, Fei Shan, Xin Ji, Qiu-Shi Dong and Jia-Fu Ji

Abstract

Background: The efficacy and safety of preoperative chemoradiation therapy (CRT) for advanced esophago-gastric adenocarcinoma are still in question, and the prognosis of these patients is poor.

Methods: We systematically searched electronic databases from January 1990 to July 2014. The primary outcome was overall survival. The secondary outcomes were a R0 resection rate, positive rate of lymph node metastasis, postoperative recurrence rate, pathological complete response (pCR) rate and perioperative mortality. Overall survival was measured with a hazard ratio (HR), while other secondary outcomes were measured with an odds ratio (OR).

Results: Seven randomized controlled trials (RCTs) including 1085 patients were searched and, of these, 869 had adenocarcinoma. Patients receiving preoperative CRT had a longer overall survival (HR 0.74; 95% confidence interval (CI) 0.63–0.88), higher likelihood of R0 resection and greater chance of pCR, while they had a lower likelihood of lymph node metastasis and postoperative recurrence. The difference of perioperative mortality was non-significant. In addition, the result of the comparison between preoperative CRT and preoperative chemotherapy (CT) in two RCTs was non-significant.

Conclusion: Patients with resectable esophago-gastric adenocarcinoma can gain a survival advantage from preoperative CRT. However, limited to the number of RCTs, the effect of adding radiotherapy to preoperative CT separately is still uncertain and more high-quality prospective trials are needed.

Keywords: Preoperative chemoradiation therapy, Esophago-gastric adenocarcinoma, Overall survival, Meta-analysis

Background

Throughout the world, adenocarcinoma of the esophagus, gastroesophageal junction and stomach rank among the most common cancers [1-3]. Additionally, during the past decade, there has been a dramatic increase in the incidence of gastro-esophageal junction cancer [4]. Adenocarcinoma accounts for a great majority of the cases of gastro-esophageal junction carcinoma in East Asia [5,6]. Furthermore, the prognosis of patients with these types of cancer is bleak [7,8]. Generally, surgery is the primary intervention for local advanced gastro-esophageal adenocarcinoma. However, the overall survival rates with surgery alone remain low, while the recurrence rates remain stubbornly high in most series [9]. The poor survival rates provide a strong rationale for the design of new treatment modalities.

As early as 1896, X-ray was first used in tumor therapy by Despeignes [10]. More than a century later, our understanding and development of radiotherapy led to a significant role in the comprehensive treatment of gastro-esophageal cancer. As patients can benefit from radiotherapy on a local control ratio, clinical experts can apply preoperative tumor down-staging and improve the resection rates of carcinoma. In addition, compared with postoperative radiotherapy, preoperative therapy is more accurate for the localization of the tumor [11]. However, as it is recognized as a systemic disease, patients with
gastro-esophageal carcinoma should undergo chemotherapy as early as possible. If chemotherapy precedes preoperative radiotherapy alone, considering the interval between radiotherapy and surgery and the possible complications after surgery, the initial time of systemic chemotherapy will be further delayed. According to the sensitization of chemotherapy [12], several phase II studies and RCTs have found that preoperative CRT has preferable safety and efficacy for local advanced gastro-esophageal adenocarcinoma [11,13-18]. Although some RCTs have proven the effectiveness of neoadjuvant chemoradiation therapy, there is the concern that meta-analysis would provide more powerful evidence for clinical decision-making relative to RCTs. However, the latest meta-analysis regarding preoperative CRT for gastro-esophageal carcinoma was published on 2007 [19], and the article only contains 3 RCTs that range from 1989 to 2006, while there were 4 new RCTs published from 2007 to 2014. Furthermore, the previous meta-analyses mostly focused on all types of gastro-esophageal carcinoma and contained not only preoperative CRTs but also preoperative chemotherapy [20,21], while this article focuses solely on adenocarcinoma and preoperative CRTs.

Methods

Literature search

To identify useful studies and published abstracts, we systematically searched electronic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Excerpta Medica Database (EMBASE), the Cochrane Database of Systematic Reviews and the China National Knowledge Infrastructure (CNKI). There were no language restrictions. The medical subject headings were listed as follows: esophagus/gastroesophageal/gastric adenocarcinoma, preoperative chemoradiation therapy, and randomized controlled trials (RCT). The search included literature published from January 1990 to July 2014. We also reviewed all abstracts that were potentially relevant to our subject. Furthermore, other grey literature as well as unpublished work, ongoing studies and negative results were searched as well. Two investigators conducted the search independently, and their results were combined.

Study review and inclusion

Two authors independently reviewed the study. The titles and abstracts were in agreement with the articles to be retrieved. To identify studies for the analysis, the inclusion criteria were designed as follows: (1) published RCTs that had a clear statement in the Materials and Methods section. (2) RCTs comparing preoperative CRT plus surgery with surgery alone or preoperative CRT plus surgery with preoperative chemotherapy plus surgery. (3) RCTs including patients with resectable, histologically proven adenocarcinoma of the esophagus, stomach or gastroesophageal junction without metastatic disease. (4) RCTs with a low risk of selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias. Bias was assessed using Begg’s and Egger’s tests [22,23]. (5) Patient survival was used as the measureable outcome.

Outcome measures

The primary outcome was overall survival, mostly based on an intention-to-treat analysis. The secondary outcomes were the R0 resection rate, which was defined by a tumor-free resection margin; positive rate of lymph node metastasis; postoperative recurrence rate; complete pathological response rate; and perioperative mortality.

Statistical analyses

Data analysis was performed using Review Manager 5.2.0 for Windows. Overall, survival was measured with a hazard ratio (HR), while the R0 resection rate, positive rate of lymph node metastasis, postoperative recurrence rate and perioperative mortality were measured using odds ratios (OR). Furthermore, intention-to-treat (ITT) analyses were conducted when possible. If permitted, HR and the corresponding standard errors were obtained directly from the article; otherwise, they were calculated using the methods of Parmar [24], Tierney [25], and Williamson [26]. These approaches use confidence intervals, log-rank p-values, number of events and Kaplan-Meier survival curves to estimate the HR and standard errors. Moreover, the measures of HR and OR were investigated for statistical heterogeneity by I² statistics, with a value of I² > 50% indicating substantial heterogeneity. Where there was evidence of heterogeneity, subgroup analysis or sensitivity analysis were performed to investigate possible bias and derived summary estimates according to the random effect model; otherwise, the Mantel-Haenszel fixed effect model was used to compute the results. All of the significance tests were two-sided, with p = 0.05 as the cutoff.

Results

Identification of studies and features of the RCTs

The results of the literature search are displayed in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram (Figure 1). A total of 1522 studies were retrieved in the database, and 4 additional studies were found from other channels, such as conference reports, and so on. Among them, 1519 records were mostly unrelated to our subject, and only 7 RCTs met our inclusion criteria, which examined a total of 1085 patients. The main features of the trials included in the meta-analysis are shown in Table 1. The seven RCTs included 869 patients with esophago-gastric adenocarcinoma, 430 of whom received CRT before surgery. Approximately 5
RCTs focused on the topic of preoperative chemoradiation therapy (CRT) followed by surgery versus surgery alone [27-31], while 2 RCTs focused on the topic of CRT followed by surgery versus preoperative chemotherapy (CT) followed by surgery [32,33]. The cancer positions involved in the 6 RCTs were of the esophagus and gastroesophageal junction, and 2 RCTs referred to the cardia. In addition, the median age of patients ranged from 56 to 65 year, and the proportion of females was 18.4%. Table 2 and Table 3 display some other characteristics regarding the RCTs included in our study. The total sample size of our meta-analysis was 1085, which contained 869 patients with adenocarcinoma, while the number of each RCTs varied greatly. The 3 year and 5 year overall survival (OS) rate are also displayed in Tables 2 and 3, where there was a certain difference between the CRT plus surgery group and the surgery alone or CT plus surgery groups. The treatment schedule is also listed (Tables 2 and 3). Additionally, no publication bias was found from the funnel plots (Figure 2).

![Diagram](image)

**Figure 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram. The figure displays the information retrieval process for valuable articles and indicates the exclusion process of irrelative articles for this research.

| Study and year | Country | Cancer position | R0 resection | Down-staging pCR of CRT | Journal publication |
|---------------|---------|-----------------|--------------|-------------------------|---------------------|
| Walsh, [27]   | Ireland | Stomach         | NM           | 13(25.0%)               | NEJM                |
|               |         | Esophagus       |              |                         |                     |
| Urba, [30]    | USA     | Stomach         | 90(92.8%)    | 9(24.3%)                | JCO                 |
|               |         | Esophagus       |              |                         |                     |
| TROG, [31]    | Australia| Esophagus       | 179(69.9%)   | NM                      | Lancet Oncol        |
| CALGB9781, [28]| USA     | Stomach         | NM           | 10(40.0%)               | JCO                 |
|               |         | Esophagus       |              |                         |                     |
| Stahl, [33]   | German  | Stomach         | 84(70.6%)    | 7(11.7%)                | JCO                 |
|               |         | Esophagus       |              |                         |                     |
| Burmeister, [32]| Australia| Stomach       | 62(82.7%)    | 5(12.8%)                | EJC                 |
|               |         | Esophagus       |              |                         |                     |
| CROSS, [29]   | Netherlands | Stomach   | 259(70.8%)   | 28(23.1%)               | NEJM                |
|               |         | Esophagus       |              |                         |                     |

**Table 1 Basic characteristics of the randomized controlled trials included**

Note: pCR: pathological complete response; CRT: preoperative chemoradiation therapy; CT: preoperative chemotherapy; NM: not mentioned.
Primary outcome
The primary outcome examined in our study was overall survival and was reported in all seven RCTs. The meta-analysis gave the result that the pooled HR was 0.74 (95% CI 0.63–0.88) for the preoperative CRT plus surgery group compared to the preoperative CT plus surgery alone groups (Figure 3). It is noteworthy that four RCTs not only contained adenocarcinoma but also contained squamous cell carcinoma (SCC) [28-31]. Therefore, the individual HR of the CROSS trial and the TROG trial, excluding SCC, were calculated separately from the data given by the original article, and the results were 0.73 (95% CI 0.54-1.00) in the CROSS trial and 1.02 (95% CI 0.72-1.44) in the TROG trial. In the CALGB9781 trial and Urba’s trial, the individual data of SCC were not displayed; however, the number of SCC in these two studies was only 37. Compared to the total number of 869, the interference of these 37 SCC patients could be ignored. As the heterogeneity test was not statistically significant ($I^2 = 13\%$), the fixed effect model was used to calculate the result for OS. Figure 3 shows Forest plots for OS. The individual HR ranged from 0.45 (95% CI 0.20-1.01) to 1.02 (95% CI 0.72-1.44) for the TROG trial; only a single individual HR favored the preoperative CRT group. This result together with those of the pooled HR indicated that there was a survival advantage for patients with preoperative CRT followed by surgery. In addition, according to the results of the heterogeneity test, there was no need to perform sensitivity analysis or subgroup analysis for the primary outcome.

Secondary outcomes
Figure 4, 5, 6, 7 show Forest plots for the secondary outcomes, including the R0 resection rate, positive rate of lymph node metastasis, postoperative recurrence rate, pathological complete response rate (pCR) and perioperative mortality. Five RCTs reported the R0 resection rate, and the individual HR was calculated from the data given by the original article. The results were 0.47 (95% CI 0.27-0.82) for the CROSS trial and 0.47 (95% CI 0.27-0.80) for the TROG trial. Compared to the pooled HR, the individual HR was not statistically significant ($I^2 = 31\%$). The fixed effect model was used to calculate the result for the R0 resection rate. Figure 4 shows the Forest plots for the R0 resection rate. The results of the heterogeneity test did not show statistical significance ($I^2 = 31\%$), so the fixed effect model was used to calculate the results. The individual HR of the CROSS trial and the TROG trial, excluding SCC, were calculated separately from the data given by the original article, and the results were 0.47 (95% CI 0.27-0.82) in the CROSS trial and 0.47 (95% CI 0.27-0.80) in the TROG trial. The individual HR of the CALGB9781 trial and Urba’s trial, excluding SCC, were calculated separately from the data given by the original article, and the results were 0.47 (95% CI 0.27-0.82) in the CALGB9781 trial and 0.47 (95% CI 0.27-0.80) in Urba’s trial. The individual HR of the Stahl trial and Burmeister trial, excluding SCC, were calculated separately from the data given by the original article, and the results were 0.47 (95% CI 0.27-0.82) in the Stahl trial and 0.47 (95% CI 0.27-0.80) in Burmeister trial. Compared to the total number of 869, the interference of these 27 SCC patients could be ignored. As the heterogeneity test was not statistically significant ($I^2 = 31\%$), the fixed effect model was used to calculate the result for the R0 resection rate. Figure 4 shows the Forest plots for the R0 resection rate. The results of the heterogeneity test did not show statistical significance ($I^2 = 31\%$), so the fixed effect model was used to calculate the results.
rate, indicating a statistically significant difference (OR 2.35, 95% CI 1.29–4.30, Figure 3). As the heterogeneity test was statistically significant ($I^2 = 59\%$), random effect modeling and subgroup analysis were performed, revealing a significant difference in the comparison between preoperative CRT and surgery alone (OR 3.55, 95% CI 2.34–5.39), while no statistically significant difference was observed in the comparison between preoperative CRT and preoperative CT (OR 1.17, 95% CI 0.61–2.27). Five RCTs reported a postoperative recurrence rate that included local and distant failure, indicating a statistically significant difference (OR 0.51, 95% CI 0.38–0.68, Figure 2), and no statistical heterogeneity was detected ($I^2 = 0\%$). Five RCTs reported the positive rate of lymph node metastasis according to the postoperative pathological report. The pooled OR was 0.30 (95% CI 0.23–0.39), revealing a significant difference, and no statistical heterogeneity was detected ($I^2 = 49\%$). Five RCTs reported perioperative mortality, and there was no statistically significant difference between the two groups (OR 1.10, 95% CI 0.62–1.93, Figure 4) nor a statistical heterogeneity ($I^2 = 0\%$). Six RCTs reported pCR after chemoradiation therapy, while two trials revealed pCR after chemotherapy, and the result of pCR in the chemoradiation therapy group was 21.56% (Table 1).

**Discussion**

Preoperative CRT has been used in the comprehensive treatment of GEJ and esophagus cancers for decades and has shown good curative effects in local control and prolonged overall survival. As early as 1978, Zhang had already carried out an elementary trial about preoperative CRT that confirmed that CRT was able to improve the results of surgery for GEJ cancer [34]. In the thirty years since, oncologists have put significant effort into the research of preoperative CRT and have had some
success in the world scope. In the America, a phase II study proved that preoperative CRT was well tolerated and comparable to similarly staged, adjuvantly treated patients [35]. In Europe, a Spanish phase II study indicated that preoperative CRT showed an acceptable toxicity and promising activity [17], while a Polish phase II study revealed that CRT was effective and showed a good toxicity profile [18]. In Asia, a Japanese phase I study indicated that CRT might cause surgery to be delayed, but showed promise for resectable advanced gastric cancer, while a Korean phase I study showed that CRT could be explored more extensively [36]. Although all of these studies indicated a tendency for preoperative CRT to obtain more powerful evidence, this meta-analysis was conducted to evaluate preoperative CRT for patients with resectable esophago-gastric adenocarcinoma.

This meta-analysis is based on 7 RCTs published from 1996 to 2012. The most important achievement of this study is the result that patients with resectable esophagogastric adenocarcinoma tended to have a survival advantage from preoperative CRT compared with surgery alone or preoperative CT followed by surgery. Although most of the individual HRs indicated no significant difference, the pooled HR revealed favorable results for the CRT group. The 3-year OS of Walsh’s study in the CRT and surgery group was 32% and 6%, while the median survival time was 16 months and 11 months (p < 0.01). Some individual data, such as the results above, indicated this opinion as well.

To identify the effect of adding radiotherapy to preoperative CT separately, we focused on the five RCTs that compared the survival benefit between preoperative CRT and surgery.
CRT and surgery alone. The pooled HR was 0.75 (95% CI 0.62-0.90), which revealed a significant difference between these two groups. On the other hand, the results of the comparison between preoperative CRT and preoperative CT in the remaining two RCTs were disappointing because the pooled HR was 0.71 (95% CI 0.48-1.05), which compared with preoperative CT meant that patients may receive a benefit from preoperative CRT, but the effect was not significant. This result was consistent with the conclusion of another meta-analysis published previously [20]. We arrived at the deduction that preoperative CRT as a whole could bring a survival advantage for patients with esophago-gastric adenocarcinoma; however, limited to the number of RCTs that compared the effect between preoperative CRT and CT, we were not able to confirm the effect of radiotherapy separately. Perhaps there was a potential difference between preoperative CRT and CT; however, this difference was not observed due to the restricted number of RCTs. Therefore, the true benefit of radiotherapy separately might be much greater, and efforts to enlarge the simple size to prove the supposition are warranted.

To determine the reason that patients with resectable esophago-gastric adenocarcinoma could receive a survival advantage from preoperative CRT, we chose the R0 resection rate, positive rate of lymph node metastasis, postoperative recurrence rate and pathological complete response rate as secondary outcomes. The final results revealed that the pooled ORs of the R0 resection rate, positive rate of lymph node metastasis and postoperative recurrence rate favored the group of preoperative CRT. Furthermore, the combined pCR rate of six RCTs was 21.56%, which approximated the results of other studies [19,37,38]. According to the data above, downstaging as a result of preoperative CRT was reflected in the significantly higher percentage of the negative rate of lymph node metastasis and pCR rate. Therefore, our analyses concluded that downstaging, the possibility of complete resection and the decreased likelihood of local recurrence which were the mechanisms of preoperative CRT, prolong survival. In addition, the pooled ORs of the R0 resection rate (OR 1.17, 95% CI 0.61-2.27) and postoperative recurrence rate (OR 0.57, 95% CI 0.32-1.02) were both non-significant, while only the pooled OR of the positive rate of lymph node metastasis (OR 0.40, 95% CI 0.22-0.72) was significant. This result also proved the conclusion above that compared with preoperative CT group; the local control rate responsible for the survival benefit was provided with a rising trend in the preoperative CRT group. However, further RCTs were necessary. Moreover, our analyses found that the pooled OR of perioperative mortality (OR

| Study or Subgroup     | CRT+Surg Events | Total | Surg/CR+Surg Events | Total | Weight | Odds Ratio M-H, Fixed, 95% CI | Odds Ratio M-H, Fixed, 95% CI |
|-----------------------|-----------------|-------|---------------------|-------|--------|-------------------|-------------------|
| Burmeister,2010,Australia | 18              | 39    | 21                  | 36    | 8.6%   | 0.61 [0.25, 1.53] |                   |
| CALGB89871,2008,USA     | 9               | 30    | 12                  | 26    | 6.6%   | 0.50 [0.17, 1.50] |                   |
| CGROSS,2012,Netherlands | 62              | 178   | 109                 | 188   | 50.7%  | 0.39 [0.26, 0.59] |                   |
| Stahl,2009,German       | 19              | 60    | 27                  | 59    | 13.7%  | 0.55 [0.26, 1.16] |                   |
| TROG,2005,Australia     | 61              | 103   | 68                  | 103   | 20.4%  | 0.75 [0.42, 1.32] |                   |
| Total (95% CI)          | 410             |       | 412                 |       | 100.0% | 0.51 [0.38, 0.68] |                   |
| Total events            | 169             |       | 237                 |       |        |                   |                   |
| Heterogeneity: Chi² = 3.57, df = 4 (P = 0.47); I² = 0% |
| Test for overall effect: Z = 4.70 (P < 0.00001) |

Figure 6 Forest plots for the secondary outcome postoperative recurrence rate. The squares and horizontal lines correspond to the study-specific HR and 95% CIs. The area of the squares reflects the study-specific weight. The diamond represents the pooled HR and 95% CI.

| Study or Subgroup     | CRT+Surg Events | Total | Surg/CT+Surg Events | Total | Weight | Odds Ratio M-H, Fixed, 95% CI | Odds Ratio M-H, Fixed, 95% CI |
|-----------------------|-----------------|-------|---------------------|-------|--------|-------------------|-------------------|
| CROSS,2012,Netherlands | 10              | 168   | 13                  | 186   | 50.6%  | 0.84 [0.36, 1.97] |                   |
| Stahl,2009,German     | 5               | 60    | 2                   | 59    | 8.1%   | 2.99 [0.48, 13.92] |                   |
| TROG,2005,Australia   | 5               | 128   | 6                   | 128   | 25.1%  | 0.83 [0.25, 2.78] |                   |
| Urba,2001,USA         | 5               | 47    | 2                   | 50    | 8.3%   | 0.52 [0.05, 5.95] |                   |
| Welsh 1996, Ireland   | 5               | 55    | 2                   | 55    | 7.9%   | 2.65 [0.49, 14.29] |                   |
| Total (95% CI)        | 458             |       | 478                 |       | 100.0% | 1.10 [0.62, 1.93] |                   |
| Total events          | 26              |       | 25                  |       |        |                   |                   |
| Heterogeneity: Chi² = 2.99, df = 4 (P = 0.56); I² = 0% |
| Test for overall effect: Z = 0.32 (P = 0.75) |

Figure 7 Forest plots for the secondary outcome perioperative mortality. The squares and horizontal lines correspond to the study-specific HR and 95% CIs. The area of the squares reflects the study-specific weight. The diamond represents the pooled HR and 95% CI.
110, 95% CI 0.62-1.93) was non-significant, which meant that preoperative CRT was safe and tolerable. There were some other valuable studies that compared the effects of preoperative CRT and surgery alone in patients with resectable esophago-gastric adenocarcinoma that were not included in this meta-analysis. The FFCD9901 trial focused on the survival outcomes for patients with localized (stages I or II) resectable esophageal carcinomas [39]; however, it is regrettable that the survival result was non-significant. We excluded this article because 75% of the patients suffered from squamous cell carcinoma and two thirds of the tumors were node-negative, which might be the cause of the negative results. Furthermore, a phase II study released on the 2013 ESMO meeting that took a therapeutic regimen as inducing chemotherapy followed by concurrent CRT before surgery reached a favorable result. The downsizing rate was 67%, while the pCR rate was 18%. This study mainly focused on the gastric adenocarcinoma and involved tumors on the antrum of the stomach. As its special value, a larger randomized trial is expected. From the clinical trial database, we also found an ongoing RCT from Australia that compared the survival differences between preoperative CRT and CT. Patients with adenocarcinoma of the stomach or gastroesophageal junction were included. It remains to be seen whether the final result will be favorable.

Conclusion
All of the studies included in our meta-analysis are RCTs, and we were fortunate to reach a significant result with slight heterogeneity, which was resolved by subgroup analyses. Therefore, our meta-analysis demonstrates that patients with resectable esophago-gastric adenocarcinoma can gain a survival advantage from preoperative CRT. However, due to the limitations of the number of RCTs, the benefit of adding radiotherapy to preoperative CT separately is still uncertain and additional high-quality prospective trials are needed.

Abbreviations
CRT: Preoperative chemoradiation therapy; pCR: Pathological complete response; HR: Hazard ratio; OR: Odds ratio; RCTs: Randomized controlled trials; CI: Confidence interval; CT: Preoperative chemotherapy; CENTRAL: Cochrane Central Register of Controlled Trials; EMBASE: Excerpta Medica Database; CNKI: China National Knowledge Infrastructure; ITT: Intention-to-treat; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; OS: Overall survival; SCC: Squamous cell carcinoma; AD: Adenocarcinoma.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
TF and QSD collected data and provided data analysis. TF, ZDB, YLZ, LHZ, XJW, AWJ designed the study and participated in writing the paper. XJ and FS participated in the design of the study and performed the statistical analysis. JFJ conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Authors’ information
1. Jia-Fu Ji: Director of Peking University Cancer Hospital , Chief expert of Gastric Cancer Collaborative Group of China, Chairman of the Gastric Cancer Association of Chinese Anti-Cancer Association, Director of International Cooperation Department of China Medical Association, Guest professor of surgery of the Gastroenterologists and Oncologists Academy in Europe , Member of American College of Surgeons, Vice chairman of Expert Committee of Nutritional Therapy for Cancer, Chairman of Tumor Examination Committee of Cross-strait Medicine Exchange Association, Member of Asian Surgical Association, Member of European Society for Clinical Nutrition and Metabolism, Evaluation experts of National Science Foundation and 863 Major Projects. 2. Department of gastrointestinal surgery of Peking University Cancer Hospital & Institute. Performing standard radical gastrointestinal surgery and multidisciplinary treatment, learning center of multidisciplinary treatment supported by Chinese Anticancer Association and The Chinese Medical Association, IASGO CME Center.

Acknowledgement
This work was supported by Beijing Science and Technology Commission and was associated with the registered clinical trial Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction Adenocarcinoma (NCT02193594). We thank the key laboratory of gastrointestinal department of Peking University Cancer Hospital & Institute for assistance with the literature search and project management.

Received: 15 January 2015 Accepted: 22 April 2015
Published online: 28 April 2015

References
1. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of esophageal cancer by histological subtype in 2012. Gut. 2014. doi:10.1136/gutjnl-2014-308124.
2. DeWeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol. 2006;13(1):12–30. doi:10.1245/ASO.2005.12.025.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.
4. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71. doi:10.3322/caac.21295.
5. Sung JJ, Ng EK, Lin JT, Ho KY, Ji JF, Sugano K, et al. Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011. J Gastroenterol Hepatol. 2012;27(9):1417–22. doi:10.1111/j.1440-1746.2012.07194.x.
6. Yang H, Wu AW, Li ZY, Bu ZD, Zhang LH, Wu XJ, et al. Surgical treatment results and prognostic analysis of 514 cases with gastroesophageal junction carcinoma. Zhonghua Wai Ke Za Zhi. 2010;48(17):1289–94.
7. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. doi:10.1038/nature13480.
8. Mansman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol. 2005;92(3):160–8. doi:10.1002/jso.20358.
9. Oppedijk V, van der Gaast A, van Lanschot JJ, Hagen P, van Os R, van Rij CM, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32(5):385–91. doi:10.1200/JCO.2013.51.2186.
10. Fairchild GC, Shorter A. Irradiation of gastric cancer. Br Med J. 1947;2(4519):243–7.
11. Pepek JM, Chino JP, Willett CG, Falta M, Blazer II, Dyer TS, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol. 2013;8:6. doi:10.1186/1748-717X-8-6.
12. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003;13(1):13–21. doi:10.1053/srao.2003.50002.
13. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001;8(8):519–24.
14. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–80. doi:10.1200/JCO.2004.01.015.
15. Posner MC, Gooding WE, Landreneau RJ, Rosenstein WM, Clarke MR, Peterson MS, et al. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Med. 1998;4(4):237–46.

16. Sakaiwa Y, Kubota T, Kumagai K, Nakamura R, Kumi K, Shigematsu N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil (5-FU) in locally advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):173–9. doi:10.1016/j.ijrobp.2007.09.010.

17. Pera M, Gallego R, Montagut C, Martin-Richard M, Iglesias M, Conill C, et al. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012;23(3):664–70. doi:10.1093/annonc/mdr291.

18. Wydmianski J, Szwinski R, Piotorok S, Maka B, Miszczyzk L, Wolny E, et al. The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. Radiother Oncol. 2007;82(2):132–6. doi:10.1016/j.radonc.2007.01.009.

19. Gelbki S, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–34. doi:10.1016/S1470-2045(07)70309-6.

20. Ronellenfitsch U, Schwarzwalb M, Hofreinzer R, Kienle P, Kieser M, Slanger TE, et al. Preoperative chemo/radiotherapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49(15):3499–508. doi:10.1016/j.ejca.2013.05.029.

21. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, et al. Randomized phase II trial of preoperative chemoradiation with oxaliplatin and fluorouracil in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;79(3):684–9. doi:10.1016/j.ijrobp.2009.11.037.

22. Koklamanos IG, Walker GR, Ferry K, Francesch C, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003;10(7):754–61.

23. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. doi:10.1016/S1470-2045(11)7042-5.

24. Mariette C. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFC9901. J Clin Oncol. 2010;28(Meeting Abstracts):4005.

25. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for the analysis of multi-centred randomized trials: a review of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–37.

26. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 2001;20(24):3993–410. doi:10.1002/1097-0258(20011230)20:24<3993::aid-sim714>3.0.co;2-n.

27. Walsh TN, Noonan N, Hollowood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–7. doi:10.1056/NEJM199607193350702.

28. Tepper J, Krama MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92. doi:10.1200/JCO.2007.12.9593.

29. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(23):2074–84. doi:10.1056/NEJMoa1112088.

30. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305–13.

31. Burmeister BH, Smithers BM, Gelbki V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(6):569–76. doi:10.1016/S1470-2045(05)70286-8.

32. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–60. doi:10.1016/j.ejca.2010.09.029.

33. Stahl A, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Kroenersch J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6. doi:10.1200/JCO.2008.17.0506.

34. Zhang ZJ, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardi (AGC)—report on 370 patients. Int J Radiat Oncol Biol Phys. 1998;42(5):929–34.

35. Ajiya JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953–8. doi:10.1200/JCO.2006.06.4840.

36. Hong YS, Lee JL, Park JH, Kim JH, Yoon SN, Lim SB, et al. Phase I study of preoperative chemoradiation with cisplatin and oxaliplatin in patients with locally advanced resectable rectal cancer. Int J Radiat Oncol Biol Phys. 2011;79(3):684–9. doi:10.1016/j.ijrobp.2009.11.037.

37. Koklamanos IG, Walker GR, Ferry K, Francesch C, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003;10(7):754–61.